Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A

Hepatology (Baltimore, Md.)1 Jul 2003Cited by 88 (Europe PMC)

PMID12830007DOI10.1053/jhep.2003.50276PepBankPUB-12830007

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS, octreotide infusion did not significantly change creatinine clearance.
In plain wordsIn cirrhotic patients with HRS, octreotide did not significantly change kidney clearance from baseline.
Peptide
Octreotide
Outcome
No significant changeCreatinine clearance
Study
n = 14
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Source sentences
Summary
In addition, treatment with octreotide infusion did not result in significant changes in creatinine clearance, daily urinary sodium, plasma renin activity, plasma aldosterone and glucagon levels, or renal and mesenteric artery resistance indices as measured by Doppler ultrasonography.
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000703
02HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS, octreotide infusion did not significantly change daily urinary sodium.
In plain wordsIn cirrhotic patients with HRS, octreotide did not significantly change daily urine sodium from baseline.
Peptide
Octreotide
Outcome
No significant changeDaily urinary sodium
Study
n = 14
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Source sentences
Summary
In addition, treatment with octreotide infusion did not result in significant changes in creatinine clearance, daily urinary sodium, plasma renin activity, plasma aldosterone and glucagon levels, or renal and mesenteric artery resistance indices as measured by Doppler ultrasonography.
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000704
03HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS, octreotide infusion did not significantly change plasma renin activity.
In plain wordsIn cirrhotic patients with HRS, octreotide did not significantly change renin activity from baseline.
Peptide
Octreotide
Outcome
No significant changePlasma renin activity
Study
n = 14
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Source sentences
Summary
In addition, treatment with octreotide infusion did not result in significant changes in creatinine clearance, daily urinary sodium, plasma renin activity, plasma aldosterone and glucagon levels, or renal and mesenteric artery resistance indices as measured by Doppler ultrasonography.
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000705
04HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS, octreotide infusion did not significantly change plasma aldosterone levels.
In plain wordsIn cirrhotic patients with HRS, octreotide did not significantly change aldosterone from baseline.
Peptide
Octreotide
Outcome
No significant changePlasma aldosterone
Study
n = 14
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Source sentences
Summary
In addition, treatment with octreotide infusion did not result in significant changes in creatinine clearance, daily urinary sodium, plasma renin activity, plasma aldosterone and glucagon levels, or renal and mesenteric artery resistance indices as measured by Doppler ultrasonography.
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000706
05HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS, octreotide infusion did not significantly change plasma glucagon levels.
In plain wordsIn cirrhotic patients with HRS, octreotide did not significantly change glucagon from baseline.
Peptide
Octreotide
Outcome
No significant changePlasma glucagon
Study
n = 14
Comparator
Baseline
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Source sentences
Summary
In addition, treatment with octreotide infusion did not result in significant changes in creatinine clearance, daily urinary sodium, plasma renin activity, plasma aldosterone and glucagon levels, or renal and mesenteric artery resistance indices as measured by Doppler ultrasonography.
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000707
06HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS, octreotide infusion did not significantly change renal artery resistance indices.
In plain wordsIn cirrhotic patients with HRS, octreotide did not significantly change kidney artery resistance from baseline.
Peptide
Octreotide
Outcome
No significant changeRenal artery resistance index
Study
n = 14
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Source sentences
Summary
In addition, treatment with octreotide infusion did not result in significant changes in creatinine clearance, daily urinary sodium, plasma renin activity, plasma aldosterone and glucagon levels, or renal and mesenteric artery resistance indices as measured by Doppler ultrasonography.
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000708
07HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS, octreotide infusion did not significantly change mesenteric artery resistance indices.
In plain wordsIn cirrhotic patients with HRS, octreotide did not significantly change intestinal artery resistance from baseline.
Peptide
Octreotide
Outcome
No significant changeMesenteric artery resistance index
Study
n = 14
Comparator
Baseline
Outcome group
Vascular function · Gastrointestinal
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Source sentences
Summary
In addition, treatment with octreotide infusion did not result in significant changes in creatinine clearance, daily urinary sodium, plasma renin activity, plasma aldosterone and glucagon levels, or renal and mesenteric artery resistance indices as measured by Doppler ultrasonography.
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000709
08HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS receiving placebo first, renal function improved in 1 patient after octreotide versus 2 after placebo; differences were not significant.
In plain wordsIn HRS patients receiving placebo first, kidney responses were fewer after octreotide than placebo, without a significant difference.
Peptide
Octreotide
Outcome
DecreaseRenal function response, placebo-first sequence
Study
n = 8
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Measurements
Patients with renal function improvement
1 patients
after octreotide, group 1 (placebo first)
Patients with renal function improvement
2 patients
after placebo, group 1 (placebo first)
Source sentences
Summary
Improvement in renal function was observed in 2 patients after the placebo and 1 patient after octreotide infusion in group 1 and in 2 patients after octreotide infusion and 1 patient after placebo in group 2 (P = not significant).
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000701
09HumanNon-randomized trialEfficacy outcome
In cirrhotic patients with HRS receiving octreotide first, renal function improved in 2 patients after octreotide versus 1 after placebo; differences were not significant.
In plain wordsIn HRS patients receiving octreotide first, kidney responses were more frequent after octreotide than placebo, without a significant difference.
Peptide
Octreotide
Outcome
IncreaseRenal function response, octreotide-first sequence
Study
n = 6
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
50 microg/h · infusion · 4 daysAs given in this study (human).
Measurements
Patients with renal function improvement
2 patients
after octreotide, group 2 (octreotide first)
Patients with renal function improvement
1 patients
after placebo, group 2 (octreotide first)
Source sentences
Summary
Improvement in renal function was observed in 2 patients after the placebo and 1 patient after octreotide infusion in group 1 and in 2 patients after octreotide infusion and 1 patient after placebo in group 2 (P = not significant).
3 context sentences(design, population, supporting numbers)
Summary · context
We compared the effects of octreotide infusion (50 microg/h) to placebo using a randomized, double-blind, cross-over design over 2, 4-day periods.
Summary · context
Nineteen patients were included, and 14 patients could complete the 2 phases of the study (group 1: placebo first; n = 8 and group 2: octreotide first; n = 6)
Summary · context
In all the patients, a normal central venous pressure was maintained by daily intravenous administration of 2 units of albumin.
Report a problemFND-1283000702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.